Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma

Cancer

Volumn 82, Issue 5, 1998, Pages 878-885

  Ribas, Antoni ^a,b   Albanell, Joan ^a   Solé Calvo, Luis Alfonso ^a   Gallardo, Enrique ^a   Bellmunt, Joaquim ^a   Vera, Ruth ^a   Vidal, Rosó ^a   Carulla, Joan ^a   Baselga, José ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biochemical modulation; Breast carcinoma; Folinic acid; Tegafur

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVITIS; DIARRHEA; DOSE RESPONSE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN TOXICITY; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIDOTES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; TEGAFUR; TREATMENT OUTCOME;

EID: 0032030873     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980301)82:5<878::AID-CNCR12>3.0.CO;2-Y     Document Type: Article

References (40)

1. Kajanti MJ, Pyrhonen SO, Maiche AG. Oral tegafur in the treatment of metastatic breast cancer: a phase II study. Eur J Cancer 1993;29A:863-6.
2. Sole LA, Albanell J, Bellmunt J, Ribas A, Gallego OS, Carulla J. Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancer. Cancer 1995;75:831-5.
3. Harris JR, Morrow M, Bonadonna G. Cancer of the breast. De Vita V, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th edition. Philadelphia: J.B. Lippincott Company, 1993:1264-332.
4. Early Breast Cancer Trialist's Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:71-85.
5. Schalhom A, Kuhl M. Clinical pharmacokinetics of fluorouracil and folinic acid. Semin Oncol 1992;19(2 Suppl 3):82-92.
6. Aschele C, Sobrero A, Faderan MA. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) subline following exposure to two different clinically relevant dose schedules. Cancer Res 1992;52:1855-64.
7. Cameron DA, Gabra H, Leonard RCF. Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 1994; 70:120-4.
8. Peters GJ, van Groeningern CJ, van der Wilt CL, Meijer S, Smid K, Laurensse E, et al. Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin. Semin Oncol 1992;19:26-35.
9. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-32.
10. Newman E, Straw J, Doroshow JH. Pharmacokinetics of the diasteroisomers of (6R,S)-folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. Cancer Res 1989;49:5755-60.
11. Etienne M-C, Guillot T, Milano G. Critical factors optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy. Ann Oncol 1996;7:283-9.
12. Erlichman C, Fine S, Wong A, Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988;6:469-75.
13. Petrelli N, Douglas HO Jr., Herrera L, Russell D, Stablein DM, Bruckner HW, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989;7:1419-26.
14. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
15. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
16. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989;7:890-9.
17. Doroshow JH, Leong L, Margolin K, Flanagan B, Goldberg D, Bruckner M, et al. Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J Clin Oncol 1989;7:439-44.
18. Jabboury K, Holmes F, Kau S, Hortobagyi G. Folinic acid modulation of low-dose fluorouracil (FU) infusion in refractory breast cancer: a dose optimization study [abstract]. Proc Am Soc Clin Oncol 1989;8:40.
19. Hainsworth JD, Andrews MB, Johnson DH, Greco FA. Mitoxantrone, fluorouracil, and high-dose leucovorin: an effective, well-tolerated regimen for metastatic breast cancer. J Clin Oncol 1991;9:1731-5.
20. Jones SE, Mennel RG, Brooks B, Westrick MA, Allison MA, Paulson RS, et al. Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast cancer. J Clin Oncol 1991;9:1736-9.
21. Hug V, Clark J, Johnston D. The results of modified use of chemotherapy for patients with metastatic breast cancer. Eur J Cancer 1994;30A:438-42.
22. Smith IE, Walsh G, Jones A, Prendiville I, Johanston S, Gusterson B, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995;13:424-9.
23. Hainsworth JD, Jones SE, Mennel RG, Blum JL, Greco FA. Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast cancer: a phase II trial. J Clin Oncol 1996;14:1611-6.
24. Jacobs EM, Reeves WJ, Wood DA, Pugh R, Braunwald J, Bateman JR. Treatment of cancer with weekly intravenous 5-fluorouracil. Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG). Cancer 1971;27:1302-5.
25. Benvenuto JA, Lu K, Hall SW, Benjamin RS, Loo TL. Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans. Cancer Res 1978;38:3867-70.
26. Pazdur R, Covington WP, Brown NS, Lassere Y, Diaz-Canton E, Ho DH. Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil [abstract]. Proc Am Soc Clin Oncol 1996;14:474.
27. Meropol NJ, Rustum YM, Petrelli NJ, Rodriguez-Bigas M, Frank C, Ho DH, et al. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer Cancer Chemother Pharmacol 1996;37:581-6.
28. Regazzoni S, Pesce G, Marini G, Cavalli F, Goldhirsch A. Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol 1996;7:807-13.
29. Breast. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ, editors. Handbook for staging of cancer. Philadelphia: J.B. Lippincott Company, 1993:161-7.
30. National Cancer Institute. Common toxicity criteria. Bethesda, MD: National Cancer Institute, 1988.
31. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:547-81.
32. Suemasu K, Nomoto C, Higashi Y. Concentration of 5-FU level in the tissue and blood of the patients with breast cancer by preoperative administration of UFT. Jpn J Cancer Chemother 1982;9:667-71.
33. Mori A, Bertoglio S, Guglielmi A, Aschele C, Bolli E, Tixi L, et al. Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 1993;33:179-80.
34. Guglielmi A, Aschele C, Grossi F, Tixi L, Sobrero A. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients. Cytotechnol 1996;19:215-9.
35. Raymond E, Palangie T, Jouve M, Asselain B, Dieras V, Beuzeboc P, et al. Protracted continuous infusion of 5-fluorouracil in combination with doxorubicin, vincristine, and oral cyclophosphamide in advanced breast cancer. Cancer Invest 1996;14:91-7.
36. Rustum YM. Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Role of dose schedule and route of administration of leucovorin. Cancer 1989;63:1013-7.
37. Hines JD, Aldelstein DJ, Spies JL, Giroski P, Carter SG. Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics. Cancer 1989;63:1022-5.
38. Schilsky RL, Choi DE, Yokes EE, Guaspari A, Guarnieri C, Whaling S, et al. Clinical pharmacology of the steroisomers of leucovorin during repeated dosing. Cancer 1989;63:018-21.
39. Margolin KA, Green S, Osborne K, Doroshow JH, Akman SA, Leong LA, et al. Phase II trial of 5-fluorouracil and high-dose folinic acid as first- or second-line therapy for advanced breast cancer. Am J Clin Oncol 1994;17:175-80.
40. Lokich JJ, Moore C. Chemotherapy-associated palmar plantar erythrodysesthesia syndrome. Ann Intern Med 1981;101: 797-800.